secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2023-06-05T23:59:59+00:00
Accession:  0001193125-23-160031
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks reports 41.3% cORR for zanidatamab in HER2-amplified BTC from Phase 2b trial
--------------------------------------------------------------------------------

- cORR of 41.3% (95% CI: 30.4-52.8) in Cohort 1 (IHC 2+/3+) by independent central review.
- Median duration of response 12.9 months; median progression-free survival 5.5 months.
- 48.5% of responders had ongoing responses at October 10, 2022 data cutoff.
- Only 2.3% of patients discontinued treatment due to adverse events; no Grade 4 or treatment-related deaths.
- Data presented at ASCO 2023 and concurrently published in The Lancet Oncology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312523160031/0001193125-23-160031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312523160031/d504484d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-160031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer